References
- Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3):33. doi:10.3390/jcm5030033.
- IHME. Acute myeloid leukemia—Level 4 cause 2019. https://www.healthdata.org/results/gbd_summaries/2019/acute-myeloid-leukemia-level-4-cause.
- Miyawaki S. Clinical studies of acute myeloid leukemia in the Japan adult leukemia study group. Int J Hematol. 2012;96(2):171–177. doi:10.1007/s12185-012-1150-6.
- Miyamoto K, Minami Y. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. Int J Clin Oncol. 2019;24(8):893–898. doi:10.1007/s10147-019-01467-1.
- Kiyoi H, Yamaguchi H, Maeda Y, et al. JSH practical guidelines for hematological malignancies, 2018: i. leukemia-1. Acute myeloid leukemia (AML). Int J Hematol. 2020;111(5):595–613. doi:10.1007/s12185-020-02856-3.
- Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3. doi:10.1186/s13045-017-0543-7.
- Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312. doi:10.1038/s41375-018-0357-9.
- Wagner K, Damm F, Thol F, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica. 2011;96(5):681–686. doi:10.3324/haematol.2010.034074.
- Capelli D, Menotti D, Fiorentini A, et al. Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure. Cancers (Basel). 2022;14(17):4315. doi:10.3390/cancers14174315.
- Astellas Announces Approval in Japan for XOSPATA® 40 mg Tablets for the Treatment of FLT3mut + Relapsed or Refractory AML [Available from https://www.astellas.com/system/files/news/2018-09/180921_3_En.pdf.
- Vanflyta (quizartinib). Prescribing information. Daiichi Sankyo Co, Ltd; 2019. [Internet]. Available from: https://www.medicalcommunity.jp/member/certification?destination=/&
- Hosono N, Yokoyama H, Aotsuka N, et al. Gilteritinib versus chemotherapy in japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol. 2021;26(11):2131–2141. doi:10.1007/s10147-021-02006-7.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi:10.1056/NEJMoa1902688.
- Dhakal PP, Pyakuryal B, Pudasainee P, et al. Treatment strategies for therapy-related acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(3):147–155. doi:10.1016/j.clml.2019.12.007.
- Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1–7. doi:10.1016/j.lrr.2016.06.001.
- Pandya BJ, Chen C-C, Medeiros BC, et al. Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database. J Manag Care Spec Pharm. 2020;26(7):849–859. doi:10.18553/jmcp.2020.19220.
- Kogushi K, Nakamura K, Ikeda S. Medical cost estimation for elderly acute myeloid leukemia (AML) using real world data in Japan. Value in Health. 2018;21:s13. doi:10.1016/j.jval.2018.07.099.
- Pandya BJ, Yang H, Schmeichel C, et al. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3 mut + acute myeloid leukemia in a US health plan. J Med Econ. 2021;24(1):19–28. doi:10.1080/13696998.2020.1851698.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196.
- National Comprehensive Cancer Network. NCCN Guidelines for Patients: Acute Myeloid Leukemia 2023. https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf
- Loschi M, Sammut R, Chiche E, et al. FLT3 tyrosine kinase inhibitors for the treatment of fit and unfit patients with FLT3-Mutated AML: a systematic review. Int J Mol Sci. 2021;22(11):5873. doi:10.3390/ijms22115873.
- Astellas Pharma Inc. Xospata Tablets Interim results of general use-results survey [Data collection period: December 3, 2018 to January 31, 2022] 2022. https://amn.astellas.jp/content/jp/amn/jp/ja/common/pdfviewer.html/content/dam/jp/amn/jp/ja/di/doc/Pdfs/DocNo202311426_y.pdf